What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

Ophthalmic Drug

PUBLISHER: 360iResearch | PRODUCT CODE: 1594677

PUBLISHER: 360iResearch | PRODUCT CODE: 1594677

Optical Disorders Drugs Market by Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs), Therapeutics (Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema), End-User - Global Forecast 2025-2030

PUBLISHED: October 31, 2024

PAGES: 197 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Optical Disorders Drugs Market was valued at USD 3.14 billion in 2023, expected to reach USD 3.56 billion in 2024, and is projected to grow at a CAGR of 13.29%, to USD 7.54 billion by 2030.

The scope of the optical disorders drugs market encompasses medications intended to treat various eye conditions, such as glaucoma, macular degeneration, diabetic retinopathy, and cataracts. These drugs are critical for maintaining eye health and vision, often acting by reducing intraocular pressure, slowing disease progression, or preventing infection. The necessity for such medications is underscored by the growing prevalence of optical disorders due to aging populations and increasing incidences of diabetes and other health conditions that can affect vision. These treatments find application in hospitals, clinics, and home care settings, ensuring a broad end-use scope.

KEY MARKET STATISTICS
Base Year [2023]	USD 3.14 billion
Estimated Year [2024]	USD 3.56 billion
Forecast Year [2030]	USD 7.54 billion
CAGR (%)	13.29%

Market growth is significantly influenced by technological advancements in drug formulations and delivery methods, increased healthcare spending, particularly in emerging economies, and rising awareness of preventative eye care. Innovation in areas such as gene therapy, personalized medicine, and the development of novel drug delivery systems like sustained-release implants present promising opportunities. Notably, collaborations and partnerships among biotech firms and research institutions can drive market advancement.

However, the market confronts several challenges, including high R&D costs leading to expensive treatments, regulatory hurdles that can delay drug approval processes, and limited accessibility in underdeveloped regions. Furthermore, the competitive landscape is intense, with numerous players striving for a share of the market, potentially leading to high pricing pressure.

To capitalize on market opportunities, companies should focus on research areas such as regenerative medicine and biologics, which hold the potential for breakthroughs in treatment efficacy and patient outcomes. Firms are also encouraged to invest in digital health solutions and teleophthalmology to reach underserved markets effectively. The nature of the market remains dynamic, driven by rapid technological advancements and evolving patient needs, requiring continuous innovation and strategic adaptability to sustain growth and relevance.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Optical Disorders Drugs Market

The Optical Disorders Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Rising demand owing to increased digital exposure and unhealthy lifestyle
- Prevalence of eye related disorders in geriatric population
- Rise in the use of contact lenses and related disorders
Market Restraints
- High treatment cost and lack of health insurance in developing economies
Market Opportunities
- Technological advancements in optic drugs
- Rising prevalence of glaucoma and an increase in healthcare expenditure
Market Challenges
- Adverse health impacts of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Optical Disorders Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Optical Disorders Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Optical Disorders Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Optical Disorders Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Optical Disorders Drugs Market

A detailed market share analysis in the Optical Disorders Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Optical Disorders Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Optical Disorders Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Optical Disorders Drugs Market

A strategic analysis of the Optical Disorders Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Optical Disorders Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch & Lomb Incorporated, Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Kiora Pharmaceuticals, Inc., Merck & Co., Inc., Nicox SA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Optical Disorders Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Prescription Type, market is studied across Over-The-Counter Drugs and Prescription Ophthalmic Drugs.
Based on Therapeutics, market is studied across Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye, Eye Cancer, Geographic Atrophy, Glaucoma, Keratitis, Lens Opacification & Intraocular Lens, and Retinal Vein Occlusion.
Based on End-User, market is studied across Diagnostic Centers, Eye Clinics, Hospitals, and Patient.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-434CCDA05224

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising demand owing to increased digital exposure and unhealthy lifestyle
  - 5.1.1.2. Prevalence of eye related disorders in geriatric population
  - 5.1.1.3. Rise in the use of contact lenses and related disorders
- 5.1.2. Restraints
  - 5.1.2.1. High treatment cost and lack of health insurance in developing economies
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancements in optic drugs
  - 5.1.3.2. Rising prevalence of glaucoma and an increase in healthcare expenditure
- 5.1.4. Challenges
  - 5.1.4.1. Adverse health impacts of drugs
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Optical Disorders Drugs Market, by Prescription Type

6.1. Introduction
6.2. Over-The-Counter Drugs
6.3. Prescription Ophthalmic Drugs

7. Optical Disorders Drugs Market, by Therapeutics

7.1. Introduction
7.2. Age-Related Macular Degeneration
7.3. Conjunctivitis
7.4. Diabetic Macular Edema
7.5. Diabetic Retinopathy
7.6. Dry Eye
7.7. Eye Cancer
7.8. Geographic Atrophy
7.9. Glaucoma
7.10. Keratitis
7.11. Lens Opacification & Intraocular Lens
7.12. Retinal Vein Occlusion

8. Optical Disorders Drugs Market, by End-User

8.1. Introduction
8.2. Diagnostic Centers
8.3. Eye Clinics
8.4. Hospitals
8.5. Patient

9. Americas Optical Disorders Drugs Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Optical Disorders Drugs Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Optical Disorders Drugs Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation

Companies Mentioned

1. AbbVie Inc.
2. Bausch & Lomb Incorporated
3. Bayer AG
4. Cipla Limited
5. F. Hoffmann-La Roche Ltd
6. GlaxoSmithKline PLC
7. Kiora Pharmaceuticals, Inc.
8. Merck & Co., Inc.
9. Nicox SA
10. Novartis AG
11. Pfizer, Inc.
12. Regeneron Pharmaceuticals Inc
13. Santen Pharmaceutical Co., Ltd.
14. Senju Pharmaceutical Co., Ltd.
15. Sun Pharmaceutical Industries Ltd.

Product Code: MRR-434CCDA05224

LIST OF FIGURES

FIGURE 1. OPTICAL DISORDERS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. OPTICAL DISORDERS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. OPTICAL DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. OPTICAL DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

TABLE 1. OPTICAL DISORDERS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. OPTICAL DISORDERS DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION OPHTHALMIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY CONJUNCTIVITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRY EYE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY KERATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY LENS OPACIFICATION & INTRAOCULAR LENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 38. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 39. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 41. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 42. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 55. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 56. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 58. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 59. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 61. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 62. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 64. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 65. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 67. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 68. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 70. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 71. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 73. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 74. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 76. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 77. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 79. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 80. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 82. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 83. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. VIETNAM OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 85. VIETNAM OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 86. VIETNAM OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 91. DENMARK OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 92. DENMARK OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 93. DENMARK OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. EGYPT OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 95. EGYPT OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 96. EGYPT OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. FINLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 98. FINLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 99. FINLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 101. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 102. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 104. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 105. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. ISRAEL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 107. ISRAEL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 108. ISRAEL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 110. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 111. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 113. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 114. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. NIGERIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 116. NIGERIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 117. NIGERIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. NORWAY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 119. NORWAY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 120. NORWAY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. POLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 122. POLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 123. POLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 125. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 126. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 131. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 132. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 134. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 135. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 137. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 138. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. SWEDEN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 140. SWEDEN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 141. SWEDEN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. SWITZERLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 143. SWITZERLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 144. SWITZERLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. TURKEY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 146. TURKEY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 147. TURKEY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. OPTICAL DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 155. OPTICAL DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023